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Randomised trials provide the most reliable evidence about the safety and effectiveness of 
interventions to improve healthcare and patient outcomes. Unfortunately, the potential for trials to 
inform treatment decisions remains limited because the outcomes reported often do not resonate with 
what is directly meaningful and relevant to patients and their clinicians[1-3]. Further, inconsistent 
reporting of outcomes across trials prevents assessment of the comparative effect of interventions[4]. 
Outcome reporting bias, whereby authors cherry pick the outcomes they report on the basis of 
favourable results, may also occur when there is not a standardised list of outcomes measured and 
reported [5, 6]. Collectively these problems may undermine the reliability of published trials, leading 
to inefficient use of scarce research and healthcare resources, and unintended harm to patients [6]. 
 
Such dissonance in outcomes reported in trials is widespread and evident across all medical 
specialties. The growing recognition of the problem has prompted large-scale efforts to establish core 
outcome sets. Core outcome sets are an agreed standardised set of outcomes for a specific clinical area 
that are to be reported as a minimum in all trials in that area[7]. Outcomes are selected because they 
are critically important to all stakeholders – namely patients, their clinicians, and policy makers – for 
decision-making. Core outcomes sets are not designed to be comprehensive or exclusive. Typically 
they include only 3-5 outcomes. Other outcomes that are identified to be important (i.e. to some 
stakeholder groups) may also be recommended for some trials (Figure 1). The designated primary 
outcome of any given trial may be outside the core outcome set, and researchers may also opt to add 
other, trial-specific outcomes, chosen for reasons including responsiveness to the intervention and 
feasibility.  
 
Attempts to standardise outcomes began 50 years ago when the World Health Organization published 
recommendations for the minimum requirements for data collection in cancer trials[8]. In the 1990s 
the Outcome Measures in Rheumatology (OMERACT) initiative was formed, and is perhaps the most 
widely recognised and largest initiative in the field of core outcome development. OMERACT 
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engages patients and health professionals to standardise outcome measures for trials in 
rheumatology[9], and has pioneered methodologies for developing core outcome sets. The uptake of 
the OMERACT core outcome sets has improved the consistency of outcomes reported in trials[10]. In 
the past decade, core outcome sets in diverse medical specialties, including cardiology, dermatology, 
surgery, oncology, women’s health, and respiratory disease, have progressively been developed[7, 9-
11].  
 
The use of core outcome sets is also increasingly being advocated by funders to ensure the relevance 
and potential impact of research. In the United Kingdom, funding organisations including the National 
Institute for Health Research and the Health Research Board (Ireland) advise researchers to include 
core outcome sets if they are available, and highlight the Core Outcome Measures in Effectiveness 
(COMET) database of core outcomes as a key resource[7]. The COMET initiative was recently 
launched to facilitate the development, implementation and evaluation of core outcome sets[7]. 
 
There has been a long-standing need in nephrology to develop core outcomes[12-14]. More than 14, 
000 randomised trials are available in the Cochrane Kidney and Transplant Specialised Register[15] 
and a search in ClinicalTrials.gov trials for “kidney disease” yields over 3000 ongoing trials. Despite 
this considerable investment into trials in nephrology, improvements in outcomes for patients with 
kidney disease have been modest at best. Across all stages of chronic kidney disease, patients still 
have a markedly higher risk of mortality and serious comorbidities including cardiovascular disease, 
diabetes, cancer, and infection, compared with the general population[16-18]. Patients with chronic 
kidney disease have poor quality of life, particularly if they are on dialysis, to the extent that many 
patients with a kidney transplant have indicated that graft survival is of a higher priority outcome 




It is difficult to estimate the impact that the lack of core outcomes in nephrology has had on patient 
care and outcomes, but a comparison between the huge research effort and the relatively small health 
gains would suggest some impact is likely. Examples of missed opportunities abound. In kidney 
transplantation, complete reporting of mortality, graft loss, and graft function (creatinine and 
estimated glomerular filtration rate) occurred in only 16% of trials on immunosuppressive 
therapy[20]; only two per cent of trials reported quality of life [21]. Quality of life outcomes, when 
reported, were almost always shown to favour the intervention, which is almost certainly due to 
selective reporting of outcomes, rather than near universal benefits of specific immunosuppressive 
agents [21]. Graft survival, mortality, life participation (ability to participate in usual activities) were 
both identified as core outcomes in the SONG-Tx (kidney transplantation process) – critically 
important to stakeholders for informing decision-making[22]. 
 
A recent systematic review of 205 trials in children with chronic kidney disease showed that the 
majority of outcomes reported were biochemical endpoints (including biochemical or physiological 
outcomes, ie, pathophysiological manifestations of health conditions). The most frequently reported 
outcome was blood pressure (37% trials), which was defined by 56 different outcome measures [14]. 
Only 14% of trials reported mortality, 4% reported cardiovascular disease, and 1% reported quality of 
life, fatigue, depression, school, or physical function [14]. These data are unconscionable. Patients, 
clinicians and research funders have a legitimate right to ask the nephrology research community a 
number of questions. Why are these outcomes chosen? Is it because of their importance to decision 
making or because of feasibility and their likelihood of being ‘positive’? Why is the same outcome 
measured in so many different ways?  
 
It is now time to break the status quo in nephrology – and perhaps we can do so with a SONG. The 
Standardised Outcomes in Nephrology (SONG) initiative was launched in 2014 to establish core 
outcomes across all stages with chronic kidney disease. In a synchronised effort, more than 2500 
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patients, caregivers, physicians, nurses and allied health professionals, regulators, funders, 
researchers, and industry partners from more than 80 countries have been involved in developing core 
outcomes. To date, these have included hemodialysis (SONG-HD)[23-27], peritoneal dialysis 
(SONG-PD), kidney transplantation (SONG-Tx)[22, 28], peritoneal dialysis (SONG-PD)[29], 
children and adolescents (SONG-Kids)[14, 30], and polycystic kidney disease (SONG-PKD). 
 
The core outcomes are developed through a validated and transparent process based on the 
OMERACT[9] and COMET[7] initiatives. The framework for establishing core outcomes involves 
systematic reviews of outcome reporting in trials, focus groups with nominal group technique with 
patients and caregivers, stakeholder interviews, an international online Delphi survey, and consensus 
workshops. The detailed methods are available in the SONG Handbook, published in June 2017[31]. 
With the core outcomes now established for haemodialysis (SONG-HD: fatigue, vascular access, 
cardiovascular disease, mortality)[24-28] and kidney transplantation (SONG-Tx: graft health, 
cardiovascular disease, cancer, infection, life participation, and mortality)[22, 28], identifying core 
validated outcome measures for each outcome is underway.  
 
The uptake of core outcomes will help to ensure that trials report outcomes that are directly relevant 
for decision-making, and thereby contribute to patient care. However, establishing and implementing 
core outcomes is not without challenges and will require engagement, dialogue, and support among 
stakeholders. We are now working with professional societies, guideline and research organisations, 
trial networks, registries, journal, funders, regulators, and patient organisations to disseminate and 
encourage the use of the SONG core outcomes. European Renal Best Practice (ERBP), an advisory 
board of the European Renal Association and European Dialysis and Transplant Association (ERA-
EDTA), produces evidence-based guidelines for healthcare professionals involved in the care of 
patients with kidney disease. In July 2017, ERBP endorsed the SONG core outcome domains, which 
will be used in relevant guidance. Other societies and organisations, including the International 
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Society of Nephrology, Canadian Society of Nephrology, the Australian and New Zealand Society of 
Nephrology, and Cochrane Kidney Transplant have also endorsed the SONG core outcomes.  
 
There are ongoing opportunities to be involved in the SONG initiative and we welcome input from the 
nephrology community to identify and implement core outcomes domains across all stages of chronic 
kidney disease. Patients with chronic kidney disease, family members, clinicians, researchers, policy 
makers, and industry, are invited to be part of the SONG initiative by registering their details via 
http://songinitiative.org/get-involved/. Working in concert and singing from the same song sheet, we 
can hope to see transformative changes in the relevance and consistency of trial outcomes to better 
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